Panagiotou's lab
@mbdlab.bsky.social
Microbiome Dynamics Department at LeibnizHKI.
We study how the microbiome impacts health, diet & ecosystems.
We study how the microbiome impacts health, diet & ecosystems.
Finally, using these signatures coupled with further mediation analysis and metabolic dependency modeling, we propose synergistic defined microbial consortia associated with NAFLD phenotype in overweight and lean individuals, respectively.
9/n
9/n
January 21, 2025 at 10:12 AM
Finally, using these signatures coupled with further mediation analysis and metabolic dependency modeling, we propose synergistic defined microbial consortia associated with NAFLD phenotype in overweight and lean individuals, respectively.
9/n
9/n
We then created ML models (RF) using bacterial species and predicted metabolites to classify NAFLD-obese and controls. These models are highly accurate and specific to NAFLD compared to other metabolic diseases.
8/n
8/n
January 21, 2025 at 10:12 AM
We then created ML models (RF) using bacterial species and predicted metabolites to classify NAFLD-obese and controls. These models are highly accurate and specific to NAFLD compared to other metabolic diseases.
8/n
8/n
We found that NAFLD-obese and NAFLD-lean individuals have different microbiome taxonic profiles than other co-ocurring metabolic diseases. Predicted metabolites (GSMM) profiles were a priori not different between groups.
7/n
7/n
January 21, 2025 at 10:12 AM
We found that NAFLD-obese and NAFLD-lean individuals have different microbiome taxonic profiles than other co-ocurring metabolic diseases. Predicted metabolites (GSMM) profiles were a priori not different between groups.
7/n
7/n
In this study, we mined public data and analyze shotgun metagenomics of 1206 patients with clear information on NAFLD status and other metabolic diseases and well-characterized clinical profiles.
6/n
6/n
January 21, 2025 at 10:12 AM
In this study, we mined public data and analyze shotgun metagenomics of 1206 patients with clear information on NAFLD status and other metabolic diseases and well-characterized clinical profiles.
6/n
6/n